Bap1 Tumor Predisposition Syndrome

Top drugs studied for this disease

All Approvals Safety alerts Label changes Trial results Research Guidance Withdrawals

CLINICAL_TRIALS withdrawal · 2026-03-17
Clinical Trial Update: Alrizomadlin (APG-115) in Subjects With BAP1 Cancer Syndrome and Early-Stage Mesothelioma [Phase 2]
Phase 2 trial of APG-115 (Alrizomadlin) for BAP1 tumor predisposition syndrome with mesothelioma has been withdrawn.